Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation within a clinical setting

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F15%3A00082232" target="_blank" >RIV/00216224:14740/15:00082232 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.haematologica.org/content/100/3/370.full-text.pdf+html" target="_blank" >http://www.haematologica.org/content/100/3/370.full-text.pdf+html</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2014.109777" target="_blank" >10.3324/haematol.2014.109777</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation within a clinical setting

Popis výsledku v původním jazyce

Next-generation sequencing has revealed novel recurrent mutations in chronic lymphocytic leukemia, particularly in patients with aggressive disease. Here, we explored targeted re-sequencing as a novel strategy to assess the mutation status of genes withprognostic potential. To this end, we utilized the HaloPlex targeted enrichment technology and designed a panel including nine genes: ATM, BIRC3, MYD88, NOTCH1, SF3B1 and TP53, that have been linked to chronic lymphocytic leukemia prognosis, and KLHL6, POT1 and XPO1, that are less characterized but were found recurrently mutated in various sequencing studies. A total of 188 chronic lymphocytic leukemia patients with poor-prognostic features (unmutated IGHV, n=137; IGHV3-21 subset #2, n=51) were sequenced on the HiSeq 2000 and data were analyzed using well-established bioinformatics tools.

Název v anglickém jazyce

Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation within a clinical setting

Popis výsledku anglicky

Next-generation sequencing has revealed novel recurrent mutations in chronic lymphocytic leukemia, particularly in patients with aggressive disease. Here, we explored targeted re-sequencing as a novel strategy to assess the mutation status of genes withprognostic potential. To this end, we utilized the HaloPlex targeted enrichment technology and designed a panel including nine genes: ATM, BIRC3, MYD88, NOTCH1, SF3B1 and TP53, that have been linked to chronic lymphocytic leukemia prognosis, and KLHL6, POT1 and XPO1, that are less characterized but were found recurrently mutated in various sequencing studies. A total of 188 chronic lymphocytic leukemia patients with poor-prognostic features (unmutated IGHV, n=137; IGHV3-21 subset #2, n=51) were sequenced on the HiSeq 2000 and data were analyzed using well-established bioinformatics tools.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

—

Svazek periodika

100

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

370-376

Kód UT WoS článku

000351279900027

EID výsledku v databázi Scopus

—